Skip to main content

Neoadjuvant Renal Cell Cancer NRG GU012 (SAMURAI)

Status: Open to Enrollment
Email us to enroll

Study details

View study details on clinicaltrials.gov.

Locations

  • Sutter Health System Wide

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic).

Christopher U Jones, M.D., FACR
Christopher U Jones, M.D., FACR
Principal investigator
View profile

Sub-Investigators

Hubert Y Pan, M.D., M.S., Nitin Rohatgi, M.D., MBA

Related clinical trials

View all clinical trials
  • Clinical trial

    Adjuvant Kidney Cancer STRIKE A032201

    Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE

    Status: Open to Enrollment

  • Clinical trial

    Advanced Clear Cell Renal Cell Carcinoma S2419

    Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]

    Status: Open to Enrollment

  • Clinical trial

    Advanced Cervical Cancer NRG GY037

    A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

    Status: Open to Enrollment

  • Clinical trial

    Advanced Staged Cancer Targeted Therapy ASCO TAPUR

    Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Status: Open to Enrollment

  • Clinical trial

    Adverse Effects of Chemotherapy Shengbai Solution

    A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?